Oncotarget

Reviews:

Functions of pancreatic stellate cellderived soluble factors in the microenvironment of pancreatic ductal carcinoma

PDF  |  Full Text  |  How to cite

Oncotarget. 2017; 8:102721-102738. https://doi.org/10.18632/oncotarget.21970

Metrics: PDF 3217 views  |  Full Text 7056 views

Qi Wu1,*, Ying Tian1,*, Jingqiu Zhang2,*, Hongpeng Zhang1, Fengming Gu1, Yongdie Lu1, Shengnan Zou1, Yuji Chen1, Pengxiang Sun1, Mengyue Xu1, Xiaoming Sun1, Chao Xia3, Hao Chi1, A Ying Zhu1, Dong Tang2 and Daorong Wang2

1Medical College of Yangzhou University, Yangzhou, P.R. China

2Department of General Surgery, Institute of General Surgery, Northern Jiangsu Province Hospital, Clinical Medical College, Yangzhou University, Yangzhou, P.R. China

3Nanjing Medical University, Nanjing, P.R. China

*These authors contributed equally to this work

Correspondence to:

Dong Tang, email: [email protected]

Daorong Wang, email: [email protected]

Keywords: transforming growth factor β(TGF-β), interleukin 6(IL-6), galectin-1, stromal cell-derived factor-1(SDF-1), hepatocyte growth factor (HGF)

Received: July 26, 2017     Accepted: September 21, 2017     Published: October 19, 2017

ABSTRACT

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal forms of cancer with poor prognosis because it is highly resistant to traditional chemotherapy and radiotherapy and it has a low rate of surgical resection eligibility. Pancreatic stellate cells (PSC) have become a research hotspot in recent years, and play a vital role in PDAC microenvironment by secreting soluble factors such as transforming growth factor β, interleukin-6, stromal cell-derived factor-1, hepatocyte growth factor and galectin-1. These PSC-derived cytokines and proteins contribute to PSC activation, participating in PDAC cell proliferation, migration, fibrosis, angiogenesis, immunosuppression, epithelial–mesenchymal transition, and chemoradiation resistance, leading to malignant outcome. Consequently, targeting these cytokines and proteins or their downstream signaling pathways is promising for treating PDAC.